Gordon J Freeman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5846532/publications.pdf

Version: 2024-02-01

449 papers	113,016 citations	151 156 h-index	160 323 g-index
458 all docs	458 docs citations	458 times ranked	78858 citing authors

#	Article	IF	Citations
1	PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 2008, 26, 677-704.	9.5	4,462
2	Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 2000, 192, 1027-1034.	4.2	4,394
3	Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006, 439, 682-687.	13.7	3,471
4	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 372, 311-319.	13.9	3,099
5	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018, 24, 1550-1558.	15.2	2,791
6	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology, 2001, 2, 261-268.	7.0	2,504
7	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006, 443, 350-354.	13.7	2,380
8	THE B7 FAMILY REVISITED. Annual Review of Immunology, 2005, 23, 515-548.	9.5	2,104
9	CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1994, 1, 405-413.	6.6	1,949
10	Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology, 2009, 10, 29-37.	7.0	1,754
11	PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. Journal of Experimental Medicine, 2009, 206, 3015-3029.	4.2	1,711
12	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	13.7	1,705
13	CD4+CD25high Regulatory Cells in Human Peripheral Blood. Journal of Immunology, 2001, 167, 1245-1253.	0.4	1,655
14	The B7â€“CD28 superfamily. Nature Reviews Immunology, 2002, 2, 116-126.	10.6	1,513
15	Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity, 2007, 27, 111-122.	6.6	1,464
16	Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 2002, 415, 536-541.	13.7	1,383
17	Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature, 2016, 537, 417-421.	13.7	1,371
18	The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nature Immunology, 2007, 8, 239-245.	7.0	1,286

#	Article	IF	Citations
19	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications, 2016, 7, 10501.	5.8	1,163
20	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 2013, 3, 1355-1363.	7.7	1,073
21	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	21.5	1,058
22	Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine, 2006, 203, 883-895.	4.2	1,042
23	Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science, 1993, 262, 909-911.	6.0	874
24	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology, 2016, 34, 2698-2704.	0.8	868
25	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. Journal of Immunology, 2003, 170, 1257-1266.	0.4	842
26	PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications, 2015, 6, 6692.	5.8	834
27	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 2016, 44, 343-354.	6.6	767
28	Rescue of exhausted CD8 T cells by PD-1â€“targeted therapies is CD28-dependent. Science, 2017, 355, 1423-1427.	6.0	753
29	Antigen-specific regulatory T cells develop via the ICOSâ€“ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nature Medicine, 2002, 8, 1024-1032.	15.2	728
30	PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research, 2013, 19, 3462-3473.	3.2	721
31	Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 2016, 34, 539-573.	9.5	718
32	Fusobacterium nucleatumin colorectal carcinoma tissue and patient prognosis. Gut, 2016, 65, 1973-1980.	6.1	718
33	Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature, 2009, 458, 206-210.	13.7	699
34	Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14733-14738.	3.3	697
35	Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma. New England Journal of Medicine, 1991, 325, 1525-1533.	13.9	678
36	Cyclin Dâ€“CDK4 kinase destabilizes PD-L1 via cullin 3â€“SPOP to control cancer immune surveillance. Nature, 2018, 553, 91-95.	13.7	660

#	Article	IF	Citations
37	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12. Immunity, 2018, 49, 1148-1161.e7.	6.6	639
38	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 2016, 34, 2690-2697.	0.8	634
39	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. Journal of Experimental Medicine, 2017, 214, 895-904.	4.2	614
40	PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. European Journal of Immunology, 2002, 32, 634.	1.6	612
41	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. Cancer Research, 2013, 73, 3591-3603.	0.4	604
42	ICOS is critical for CD40-mediated antibody class switching. Nature, 2001, 409, 102-105.	13.7	597
43	Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nature Immunology, 2003, 4, 1102-1110.	7.0	564
44	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10691-10696.	3.3	556
45	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. European Journal of Immunology, 2003, 33, 2706-2716.	1.6	551
46	B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity, 1995, 2, 523-532.	6.6	548
47	TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells. Immunity, 2007, 27, 927-940.	6.6	536
48	TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunological Reviews, 2010, 235, 172-189.	2.8	531
49	Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6586-6590.	3.3	519
50	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
51	Fusobacterium nucleatumand T Cells in Colorectal Carcinoma. JAMA Oncology, 2015, 1, 653.	3.4	498
52	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
53	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nature Immunology, 2007, 8, 1246-1254.	7.0	485
54	B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center Formation. Immunity, 1997, 6, 303-313.	6.6	479

#	Article	IF	Citations
55	LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell, 2018, 174, 549-563.e19.	13.5	473
56	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 764-782.	1.1	469
57	In vivo imaging reveals a tumor-associated macrophageâ€“mediated resistance pathway in antiâ€“PD-1 therapy. Science Translational Medicine, 2017, 9, .	5.8	466
58	Selective expansion of a subset of exhausted CD8 T cells by Î±PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15016-15021.	3.3	462
59	Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity, 2016, 44, 955-972.	6.6	462
60	Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nature Immunology, 2001, 2, 1109-1116.	7.0	460
61	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.4	451
62	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nature Medicine, 2010, 16, 1147-1151.	15.2	448
63	Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression. Journal of Virology, 2007, 81, 2545-2553.	1.5	431
64	Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016, 127, 869-881.	0.6	429
65	B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6575-6579.	3.3	424
66	Enhancing CD8+ T Cell Fatty Acid Catabolism withinÂa Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell, 2017, 32, 377-391.e9.	7.7	419
67	CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion. Journal of Experimental Medicine, 2004, 199, 1479-1489.	4.2	416
68	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances, 2018, 4, eaar2766.	4.7	416
69	Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. European Journal of Immunology, 2003, 33, 3117-3126.	1.6	413
70	Maintenance of Human T Cell Anergy: Blocking of IL-2 Gene Transcription by Activated Rap1. Science, 1997, 278, 124-128.	6.0	408
71	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity, 2019, 50, 1498-1512.e5.	6.6	406
72	Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells. Journal of Immunology, 2000, 165, 5035-5040.	0.4	400

#	Article	IF	Citations
73	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity, 2017, 46, 197-204.	6.6	400
74	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	7.7	392
75	RIAM, an Ena/VASP and Profilin Ligand, Interacts with Rap1-GTP and Mediates Rap1-Induced Adhesion. Developmental Cell, 2004, 7, 585-595.	3.1	382
76	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 2018, 25, 2972-2980.e5.	2.9	381
77	Reinvigorating exhausted HIV-specific T cells via PD-1â€“PD-1 ligand blockade. Journal of Experimental Medicine, 2006, 203, 2223-2227.	4.2	374
78	Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science, 1993, 262, 907-909.	6.0	368
79	Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.. Journal of Experimental Medicine, 1993, 178, 2185-2192.	4.2	363
80	The importance of exosomal PDL1 inÂtumour immune evasion. Nature Reviews Immunology, 2020, 20, 209-215.	10.6	360
81	The TIM gene family: emerging roles in immunity and disease. Nature Reviews Immunology, 2003, 3, 454-462.	10.6	355
82	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research, 2015, 21, 3031-3040.	3.2	355
83	Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. Immunity, 2019, 51, 1043-1058.e4.	6.6	353
84	Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nature Medicine, 2013, 19, 494-499.	15.2	342
85	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research, 2016, 4, 124-135.	1.6	339
86	T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nature Communications, 2017, 8, 1747.	5.8	336
87	Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.. Journal of Experimental Medicine, 1991, 174, 625-631.	4.2	332
88	Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression. Cancer Cell, 2014, 25, 590-604.	7.7	332
89	Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma. American Journal of Surgical Pathology, 2006, 30, 802-810.	2.1	331
90	Role of PD-1 during effector CD8 T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4749-4754.	3.3	327

#	Article	IF	Citations
91	Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade. PLoS Pathogens, 2009, 5, e1000313.	2.1	322
92	The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy. Cancer Discovery, 2015, 5, 16-18.	7.7	319
93	Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection.. Journal of Experimental Medicine, 1989, 170, 145-161.	4.2	315
94	Selective induction of B7/BB-1 on interferon-Î³ stimulated monocytes: A potential mechanism for amplification of T cell activation through the CD28 pathway. Cellular Immunology, 1991, 137, 429-437.	1.4	313
95	CTLA4 mediates antigen-specific apoptosis of human T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 811-815.	3.3	312
96	CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nature Immunology, 2008, 9, 176-185.	7.0	311
97	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science, 1994, 266, 1039-1042.	6.0	303
98	Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell:T Cell Interactions. Immunity, 1999, 11, 689-698.	6.6	293
99	TIM-family Proteins Promote Infection of Multiple Enveloped Viruses through Virion-associated Phosphatidylserine. PLoS Pathogens, 2013, 9, e1003232.	2.1	288
100	Induction of T helper type 1â€“like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nature Immunology, 2004, 5, 1149-1156.	7.0	287
101	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 480-492.	1.6	284
102	Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature, 1992, 360, 266-268.	13.7	279
103	TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nature Immunology, 2005, 6, 447-454.	7.0	278
104	Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7663-7667.	3.3	269
105	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNÎ³ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Research, 2016, 76, 1031-1043.	0.4	265
106	CD161 Defines a Transcriptional and Functional Phenotype across Distinct Human T Cell Lineages. Cell Reports, 2014, 9, 1075-1088.	2.9	264
107	Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization. Gastroenterology, 2008, 134, 1927-1937.e2.	0.6	263
108	T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells. Journal of Immunology, 2010, 184, 1918-1930.	0.4	262

#	Article	IF	Citations
109	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood, 2017, 130, 2420-2430.	0.6	262
110	The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating Tâ€cell activation. Immunological Reviews, 2009, 229, 244-258.	2.8	260
111	Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. Scientific Reports, 2017, 7, 1878.	1.6	260
112	Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5687-5690.	3.3	259
113	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 2016, 7, 34341-34355.	0.8	258
114	ICOS:ICOS-Ligand Interaction Is Required for Type 2 Innate Lymphoid Cell Function, Homeostasis, and Induction of Airway Hyperreactivity. Immunity, 2015, 42, 538-551.	6.6	254
115	Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer. Cancer Research, 2013, 73, 6900-6912.	0.4	253
116	Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nature Immunology, 2001, 2, 1174-1182.	7.0	250
117	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunology Letters, 2002, 84, 57-62.	1.1	249
118	PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology, 2014, 25, 2178-2184.	0.6	249
119	RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. Journal of Experimental Medicine, 2014, 211, 943-959.	4.2	249
120	Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11780-11785.	3.3	248
121	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget, 2016, 7, 32925-32932.	0.8	248
122	Induction of Robust Cellular and Humoral Virus-Specific Adaptive Immune Responses in Human Immunodeficiency Virus-Infected Humanized BLT Mice. Journal of Virology, 2009, 83, 7305-7321.	1.5	247
123	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Annals of Oncology, 2015, 26, 812-817.	0.6	246
124	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. Journal of Clinical Investigation, 2013, 123, 2604-2615.	3.9	245
125	Strength of PD-1 signaling differentially affects T-cell effector functions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2480-9.	3.3	242
126	Interferon-Î³-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. OncoImmunology, 2015, 4, e1008824.	2.1	238

#	Article	IF	Citations
127	In-Fusionâ„¢ assembly: seamless engineering of multidomain fusion proteins, modular vectors, and mutations. BioTechniques, 2007, 43, 354-359.	0.8	237
128	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	1.6	237
129	Isolated human follicular dendritic cells display a unique antigenic phenotype.. Journal of Experimental Medicine, 1989, 169, 2043-2058.	4.2	230
130	Expression and Regulation of the PD-L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells. Microcirculation, 2002, 9, 133-145.	1.0	230
131	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654.	1.6	226
132	Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8⁺T-Cellâ€“Mediated Injury in the Heart. Circulation, 2007, 116, 2062-2071.	1.6	221
133	Interaction of human PD-L1 and B7-1. Molecular Immunology, 2008, 45, 3567-3572.	1.0	219
134	p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nature Medicine, 2000, 6, 290-297.	15.2	216
135	PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver. Journal of Immunology, 2007, 178, 2714-2720.	0.4	214
136	PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues. Journal of Immunology, 2007, 179, 5064-5070.	0.4	212
137	Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults. Journal of Immunology, 2011, 186, 4200-4212.	0.4	211
138	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	13.5	210
139	Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11059-11063.	3.3	208
140	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1726-1735.	0.5	208
141	Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15430-15435.	3.3	206
142	Structures of T Cell Immunoglobulin Mucin Protein 4 Show a Metal-Ion-Dependent Ligand Binding Site where Phosphatidylserine Binds. Immunity, 2007, 27, 941-951.	6.6	206
143	B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance.. Journal of Experimental Medicine, 1993, 178, 1753-1763.	4.2	202
144	Enhancing therapeutic vaccination by blocking PD-1â€“mediated inhibitory signals during chronic infection. Journal of Experimental Medicine, 2008, 205, 543-555.	4.2	201

#	Article	IF	Citations
145	Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8200-8204.	3.3	200
146	Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4210-4214.	3.3	199
147	An Autoimmune Disease-Associated CTLA-4 Splice Variant Lacking the B7 Binding Domain Signals Negatively in T Cells. Immunity, 2004, 20, 563-575.	6.6	197
148	High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8 ⁺ and CD4 ⁺ T Cells during Acute HCV Infection, Irrespective of Clinical Outcome. Journal of Virology, 2008, 82, 3154-3160.	1.5	193
149	Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1100-1107.	1.1	189
150	Hepatitis A virus link to atopic disease. Nature, 2003, 425, 576-576.	13.7	186
151	IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20428-20433.	3.3	186
152	Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discovery, 2017, 7, 1098-1115.	7.7	185
153	Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. Journal of Experimental Medicine, 2015, 212, 1603-1621.	4.2	183
154	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. Journal of Experimental Medicine, 2014, 211, 1905-1918.	4.2	182
155	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nature Cell Biology, 2020, 22, 1064-1075.	4.6	182
156	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood, 2014, 123, 3988-3998.	0.6	179
157	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut, 2017, 66, 1463-1473.	6.1	173
158	Breast cancerâ€“associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Medicine, 1996, 2, 1367-1370.	15.2	164
159	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	0.6	164
160	PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Research, 2017, 77, 6353-6364.	0.4	161
161	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.4	159
162	Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3137-3141.	3.3	158

#	Article	IF	Citations
163	Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood, 2011, 118, 965-974.	0.6	158
164	PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunology, 2010, 3, 81-91.	2.7	157
165	Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood, 2006, 107, 1528-1536.	0.6	156
166	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood, 2013, 122, 3062-3073.	0.6	156
167	Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21182-21187.	3.3	155
168	Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15001-15006.	3.3	154
169	The Role of B7-1/B7-2:CD28/CLTA-4 Pathways in the Prevention of Anergy, Induction of Productive Immunity and Down-Regulation of the Immune Response. Immunological Reviews, 1996, 153, 5-26.	2.8	153
170	Type 2 innate lymphoid cell suppression by regulatory TÂcells attenuates airway hyperreactivity and requires inducible T-cell costimulatorâ€“inducible T-cell costimulator ligand interaction. Journal of Allergy and Clinical Immunology, 2017, 139, 1468-1477.e2.	1.5	153
171	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology, 2017, 12, 1268-1279.	0.5	152
172	PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. Aids, 2007, 21, 2005-2013.	1.0	151
173	PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. Journal of Experimental Medicine, 2021, 218, .	4.2	151
174	Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules.. Journal of Clinical Investigation, 1995, 95, 1415-1421.	3.9	149
175	Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. Journal of Immunology, 1998, 160, 1532-8.	0.4	149
176	Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. Journal of Immunology, 2006, 177, 4196-4202.	0.4	148
177	INHIBITION OF TRANSPLANT REJECTION FOLLOWING TREATMENT WITH ANTI-B7-2 AND ANTI-B7-1 ANTIBODIES. Transplantation, 1995, 60, 1171-1178.	0.5	147
178	Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation, 2002, 9, 133-45.	1.0	146
179	Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11336-11341.	3.3	144
180	CD226 Is Specifically Expressed on the Surface of Th1 Cells and Regulates Their Expansion and Effector Functions. Journal of Immunology, 2005, 175, 1558-1565.	0.4	143

#	Article	IF	Citations
181	PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nature Immunology, 2019, 20, 1335-1347.	7.0	142
182	Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load. Immunity, 2011, 35, 285-298.	6.6	141
183	Interleukin 6 gene expression in normal and neoplastic B cells.. Journal of Clinical Investigation, 1989, 83, 1512-1518.	3.9	141
184	Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model. Cell, 2012, 148, 739-751.	13.5	139
185	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
186	Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain. American Journal of Surgical Pathology, 2014, 38, 1715-1723.	2.1	138
187	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	7.7	138
188	PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. Journal of Clinical Investigation, 2012, 122, 1712-1716.	3.9	138
189	Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Current Opinion in Immunology, 1994, 6, 797-807.	2.4	137
190	Cloning of Ly-5 cDNA.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7360-7363.	3.3	135
191	PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunology Research, 2018, 6, 921-929.	1.6	133
192	Early signaling defects in human T cells anergized by T cell presentation of autoantigen.. Journal of Experimental Medicine, 1992, 176, 177-186.	4.2	132
193	In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma. Cancer Discovery, 2020, 10, 270-287.	7.7	129
194	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	0.8	127
195	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunology Research, 2015, 3, 1123-1129.	1.6	127
196	Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression. Journal of Biological Chemistry, 2015, 290, 8110-8120.	1.6	126
197	Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 271-275.	3.3	125
198	Ex Vivo Generation of Human Antiâ€“Pre-B Leukemia-Specific Autologous Cytolytic T Cells. Blood, 1997, 90, 549-561.	0.6	125

#	Article	IF	Citations
199	Role of PD-1 in regulating acute infections. Current Opinion in Immunology, 2010, 22, 397-401.	2.4	125
200	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight, 2016, 1, e87415.	2.3	125
201	Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. Journal of Clinical Investigation, 2010, 120, 3878-3890.	3.9	123
202	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. Journal of Immunology, 2005, 175, 7372-7379.	0.4	122
203	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncology, 2016, 2, 518.	3.4	121
204	The BAL-binding Protein BBAP and Related Deltex Family Members Exhibit Ubiquitin-Protein Isopeptide Ligase Activity. Journal of Biological Chemistry, 2003, 278, 21930-21937.	1.6	120
205	Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-Specific CD8 T Cells during Chronic Infection but Not after Vaccination. Journal of Virology, 2007, 81, 5819-5828.	1.5	119
206	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. Journal of Immunology, 2011, 187, 1113-1119.	0.4	115
207	The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase.. Journal of Cell Biology, 1992, 116, 423-435.	2.3	114
208	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	1.6	114
209	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation, 2003, 112, 234-243.	3.9	114
210	Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells.. Journal of Experimental Medicine, 1992, 175, 951-960.	4.2	113
211	Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood, 2005, 105, 3372-3380.	0.6	113
212	Defective TFH Cell Function and Increased TFR Cells Contribute to Defective Antibody Production in Aging. Cell Reports, 2015, 12, 163-171.	2.9	112
213	Tissue-Specific Differences in PD-1 and PD-L1 Expression during Chronic Viral Infection: Implications for CD8 T-Cell Exhaustion. Journal of Virology, 2010, 84, 2078-2089.	1.5	111
214	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	110
215	CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.. Journal of Experimental Medicine, 1994, 180, 1665-1673.	4.2	109
216	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	0.8	109

#	Article	IF	Citations
217	The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungusHistoplasma capsulatum. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2658-2663.	3.3	107
218	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	1.6	106
219	Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade. Journal of Immunology, 2009, 182, 2102-2112.	0.4	105
220	Tyk2 Negatively Regulates Adaptive Th1 Immunity by Mediating IL-10 Signaling and Promoting IFN-Î³-Dependent IL-10 Reactivation. Journal of Immunology, 2006, 176, 7263-7271.	0.4	104
221	Role of the CD40 and CD95 (APOâ€1/Fas) antigens in the apoptosis of human Bâ€cell malignancies. British Journal of Haematology, 1997, 97, 409-417.	1.2	103
222	The Role of LAT in Increased CD8 ⁺ T Cell Exhaustion in Trigeminal Ganglia of Mice Latently Infected with Herpes Simplex Virus 1. Journal of Virology, 2011, 85, 4184-4197.	1.5	103
223	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discovery, 2021, 11, 1524-1541.	7.7	103
224	The Function of Donor versus Recipient Programmed Death-Ligand 1 in Corneal Allograft Survival. Journal of Immunology, 2007, 179, 3672-3679.	0.4	101
225	Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. Journal of Leukocyte Biology, 2010, 89, 507-515.	1.5	100
226	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget, 2016, 7, 76565-76576.	0.8	100
227	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. , 2016, 4, 65.		100
228	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clinical Cancer Research, 2021, 27, 276-287.	3.2	100
229	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular Cell, 2021, 81, 2317-2331.e6.	4.5	97
230	Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function. Journal of Immunology, 2018, 200, 2592-2602.	0.4	96
231	Impaired Hepatitis C Virus (HCV)-Specific Effector CD8 ⁺ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection. Journal of Virology, 2008, 82, 9808-9822.	1.5	93
232	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunology, Immunotherapy, 2019, 68, 421-432.	2.0	93
233	CD48-deficient mice have a pronounced defect in CD4+ T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1019-1023.	3.3	92
234	Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16971-16980.	3.3	92

#	Article	IF	Citations
235	VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends in Immunology, 2021, 42, 209-227.	2.9	92
236	Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Communications Biology, 2020, 3, 128.	2.0	91
237	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clinical Cancer Research, 2019, 25, 290-299.	3.2	88
238	Minicircle DNA-based Gene Therapy Coupled With Immune Modulation Permits Long-term Expression of Î±-L-Iduronidase in Mice With Mucopolysaccharidosis Type I. Molecular Therapy, 2011, 19, 450-460.	3.7	86
239	PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads. PLoS ONE, 2013, 8, e77780.	1.1	85
240	Antiâ€PDâ€1/PDâ€L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. International Journal of Cancer, 2019, 144, 2266-2278.	2.3	84
241	Emerging concepts in PD-1 checkpoint biology. Seminars in Immunology, 2021, 52, 101480.	2.7	84
242	4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection. Journal of Immunology, 2011, 187, 1634-1642.	0.4	83
243	Highâ€fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. Journal of Extracellular Vesicles, 2019, 8, 1597603.	5.5	83
244	Combination antiâ€“PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight, 2018, 3, .	2.3	83
245	Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation.. Journal of Experimental Medicine, 1996, 184, 365-376.	4.2	82
246	Liver Environment and HCV Replication Affect Human T-Cell Phenotype and Expression of Inhibitory Receptors. Gastroenterology, 2014, 146, 550-561.	0.6	82
247	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2016, 4, 679-687.	1.6	81
248	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. Journal of Clinical Investigation, 2016, 126, 2642-2660.	3.9	81
249	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget, 2016, 7, 17194-17211.	0.8	80
250	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2018, 6, 1234-1245.	1.6	80
251	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80
252	A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB.. Journal of Experimental Medicine, 1996, 183, 777-789.	4.2	79

#	Article	IF	Citations
253	ICOS/ICOSL Interaction Is Required for CD4+ Invariant NKT Cell Function and Homeostatic Survival. Journal of Immunology, 2008, 180, 5448-5456.	0.4	79
254	PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. European Journal of Immunology, 2006, 36, 58-64.	1.6	78
255	Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ TÂcells. Cell Metabolism, 2022, 34, 1137-1150.e6.	7.2	78
256	TIM-4, a Receptor for Phosphatidylserine, Controls Adaptive Immunity by Regulating the Removal of Antigen-Specific T Cells. Journal of Immunology, 2010, 185, 6839-6849.	0.4	77
257	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
258	B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. Journal of Clinical Investigation, 2001, 107, 881-887.	3.9	76
259	Telomerase activity of HIV-1â€“specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood, 2008, 112, 3679-3687.	0.6	75
260	CD4+ CD25+ Regulatory Cells from Human Peripheral Blood Express Very High Levels of CD25 Ex Vivo. Novartis Foundation Symposium, 2008, 252, 67-91.	1.2	75
261	Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. British Journal of Cancer, 2018, 119, 1223-1232.	2.9	72
262	The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. Cell Reports, 2020, 31, 107827.	2.9	72
263	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. Nature Cancer, 2021, 2, 503-514.	5.7	72
264	Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. International Immunology, 1995, 7, 957-966.	1.8	71
265	PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques. Science Immunology, 2021, 6, .	5.6	70
266	PTPROt: An Alternatively Spliced and Developmentally Regulated B-Lymphoid Phosphatase That Promotes G0/G1 Arrest. Blood, 1999, 94, 2403-2413.	0.6	68
267	Critical role of CD81 in cognate Tâ€“B cell interactions leading to Th2 responses. International Immunology, 2002, 14, 513-523.	1.8	68
268	A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. Journal of Clinical Investigation, 2011, 121, 1111-1118.	3.9	68
269	Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9778-9783.	3.3	67
270	Apoptotic Cells Activate NKT Cells through T Cell Ig-Like Mucin-Likeâ€“1 Resulting in Airway Hyperreactivity. Journal of Immunology, 2010, 185, 5225-5235.	0.4	67

#	Article	IF	Citations
271	Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. Journal of Leukocyte Biology, 2013, 93, 825-836.	1.5	66
272	OX40- and CD27-Mediated Costimulation Synergizes with Antiâ€“PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence. Journal of Immunology, 2015, 194, 125-133.	0.4	65
273	RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1475-E1484.	3.3	65
274	Expression and regulation of CD5 onin vitro activated human B cells. European Journal of Immunology, 1989, 19, 849-855.	1.6	64
275	PD-1 ligands, negative regulators for activation of naÃ¯ve, memory, and recently activated human CD4+ T cells. Cellular Immunology, 2004, 230, 89-98.	1.4	64
276	Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10734-10739.	3.3	64
277	Intercellular Adhesion Molecule 1 Is Critical for Activation of CD28-Deficient T Cells. Journal of Immunology, 2000, 165, 6091-6098.	0.4	63
278	Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood, 2008, 112, 2149-2155.	0.6	63
279	Examination of CD8+ T Cell Function in Humans Using MHC Class I Tetramers: Similar Cytotoxicity but Variable Proliferation and Cytokine Production Among Different Clonal CD8+ T Cells Specific to a Single Viral Epitope. Journal of Immunology, 2000, 165, 6214-6220.	0.4	62
280	Learning from PD-1 Resistance: New Combination Strategies. Trends in Molecular Medicine, 2016, 22, 448-451.	3.5	61
281	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro-Oncology, 2018, 20, 225-235.	0.6	61
282	Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10275-10276.	3.3	60
283	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Review of Vaccines, 2013, 12, 597-615.	2.0	60
284	Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation. Journal of Immunology, 2009, 183, 7898-7908.	0.4	58
285	Differential Impact of PD-1 and/or Interleukin-10 Blockade on HIV-1-Specific CD4 T Cell and Antigen-Presenting Cell Functions. Journal of Virology, 2014, 88, 2508-2518.	1.5	58
286	Regulation of T-Cell Chemotaxis by Programmed Death-Ligand 1 (PD-L1) in Dry Eyeâ€“Associated Corneal Inflammation. , 2010, 51, 3418.		57
287	Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood, 2008, 112, 1662-1672.	0.6	56
288	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research, 2021, 9, 156-169.	1.6	56

#	Article	IF	Citations
289	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood, 2015, 125, 3335-3346.	0.6	55
290	The 4F9 Antigen Is a Member of the Tetra Spans Transmembrane Protein Family and Functions as an Accessory Molecule in T Cell Activation and Adhesion. Cellular Immunology, 1993, 152, 249-260.	1.4	54
291	The Human Semaphorin-like Leukocyte Cell Surface Molecule CD100 Associates with a Serine Kinase Activity. Journal of Biological Chemistry, 1997, 272, 23515-23520.	1.6	54
292	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine, 2021, 13, .	5.8	54
293	Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptorâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 456-465.	1.1	53
294	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. OncoImmunology, 2018, 7, e1442999.	2.1	53
295	Immunoglobulin A (IgA) Is a Natural Ligand of Hepatitis A Virus Cellular Receptor 1 (HAVCR1), and the Association of IgA with HAVCR1 Enhances Virus-Receptor Interactions. Journal of Virology, 2007, 81, 3437-3446.	1.5	52
296	Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clinical Immunology, 2008, 126, 140-147.	1.4	52
297	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. Journal of Clinical Investigation, 2010, 120, 3855-3868.	3.9	52
298	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. American Journal of Surgical Pathology, 2016, 40, 443-453.	2.1	51
299	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. Journal of Immunology, 2018, 201, 971-981.	0.4	50
300	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	3.2	50
301	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. Journal of Clinical Investigation, 2003, 112, 234-243.	3.9	50
302	LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. Journal of Immunology, 2016, 196, 2085-2094.	0.4	49
303	TSC2-deficient tumors have evidence of T cell exhaustion and respond to antiâ€“PD-1/antiâ€“CTLA-4 immunotherapy. JCI Insight, 2018, 3, .	2.3	49
304	Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discovery, 2020, 10, 1296-1311.	7.7	49
305	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
306	B7-2 Expressed on EL4 Lymphoma Suppresses Antitumor Immunity by an Interleukin 4â€“dependent Mechanism. Journal of Experimental Medicine, 1999, 189, 919-930.	4.2	48

#	Article	IF	Citations
307	Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. European Journal of Immunology, 1993, 23, 283-286.	1.6	47
308	Binding of Hepatitis A Virus to Its Cellular Receptor 1 Inhibits T-Regulatory Cell Functions in Humans. Gastroenterology, 2012, 142, 1516-1525.e3.	0.6	47
309	CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunology, Immunotherapy, 2013, 62, 347-357.	2.0	47
310	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	1.6	46
311	A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clinical Cancer Research, 2015, 21, 2201-2203.	3.2	45
312	USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nature Communications, 2022, 13, 1700.	5.8	45
313	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumorsâ€”Response. Cancer Research, 2014, 74, 633-634.	0.4	44
314	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunology Research, 2017, 5, 1046-1055.	1.6	42
315	A Novel Alloantigen-Specific CD8+PD1+ Regulatory T Cell Induced by ICOS-B7h Blockade In Vivo. Journal of Immunology, 2007, 179, 786-796.	0.4	41
316	Inhibitory TCR Coreceptor PD-1 Is a Sensitive Indicator of Low-Level Replication of SIV and HIV-1. Journal of Immunology, 2010, 184, 476-487.	0.4	41
317	TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Research, 2022, 50, D1391-D1397.	6.5	41
318	Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis. Ocular Immunology and Inflammation, 2009, 17, 47-55.	1.0	39
319	Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. International Immunology, 1999, 11, 407-416.	1.8	38
320	Variable Patterns of Programmed Death-1 Expression on Fully Functional Memory T Cells after Spontaneous Resolution of Hepatitis C Virus Infection. Journal of Virology, 2008, 82, 5109-5114.	1.5	38
321	TIM-4, expressed by medullary macrophages, regulates respiratory tolerance by mediating phagocytosis of antigen-specific T cells. Mucosal Immunology, 2013, 6, 580-590.	2.7	38
322	RNA synthesis of vesicular stomatits virus VIII. Oligonucleotides of the structural genes and mRNA. Gene, 1979, 5, 141-157.	1.0	37
323	Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. Journal of Immunology, 1997, 159, 4799-805.	0.4	37
324	Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. Clinical Cancer Research, 2021, 27, 2816-2826.	3.2	36

#	Article	IF	Citations
325	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
326	Biologic Activity of Autologous, Granulocyteâ€“Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	3.2	34
327	The Leukocyte Semaphorin CD100 Is Expressed in Most T-Cell, but Few B-Cell, Non-Hodgkin's Lymphomas. American Journal of Pathology, 1998, 153, 255-262.	1.9	33
328	Rap1-GTP Is a Negative Regulator of Th Cell Function and Promotes the Generation of CD4+CD103+ Regulatory T Cells In Vivo. Journal of Immunology, 2005, 175, 3133-3139.	0.4	33
329	Intact <scp>B</scp>7â€<scp>H</scp>3 signaling promotes allograft prolongation through preferential suppression of <scp>T</scp>h1 effector responses. European Journal of Immunology, 2012, 42, 2343-2353.	1.6	33
330	Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis. Frontiers in Immunology, 2017, 8, 851.	2.2	33
331	The ICOS-ligand B7-H2, expressed on human type II alveolar epithelial cells, plays a role in the pulmonary host defense system. European Journal of Immunology, 2006, 36, 906-918.	1.6	32
332	Simian Immunodeficiency Virus (SIV)-Specific CD8⁺T-Cell Responses in Vervet African Green Monkeys Chronically Infected with SIVagm. Journal of Virology, 2008, 82, 11577-11588.	1.5	32
333	The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. International Immunology, 1997, 9, 805-813.	1.8	31
334	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer, 2016, 2, 16002.	2.3	31
335	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.2	31
336	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 1353-1364.	0.6	31
337	Activation primes human B lymphocytes to respond to heat shock.. Journal of Experimental Medicine, 1989, 170, 1763-1768.	4.2	30
338	MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunology Research, 2016, 4, 33-40.	1.6	29
339	Cutting Edge: CD94/NKG2 Is Expressed on Th1 But Not Th2 Cells and Costimulates Th1 Effector Functions. Journal of Immunology, 2002, 169, 5382-5386.	0.4	28
340	PD-1 on Immature and PD-1 Ligands on Migratory Human Langerhans Cells Regulate Antigen-Presenting Cell Activity. Journal of Investigative Dermatology, 2010, 130, 2222-2230.	0.3	28
341	The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. Human Pathology, 2010, 41, 1486-1494.	1.1	28
342	CD160 Stimulates CD8+ T Cell Responses and Is Required for Optimal Protective Immunity toListeria monocytogenes. ImmunoHorizons, 2018, 2, 238-250.	0.8	28

#	Article	IF	Citations
343	Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.. , 2013, , .		26
344	CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival. PLoS ONE, 2013, 8, e60391.	1.1	25
345	T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death. Journal of Allergy and Clinical Immunology, 2013, 132, 414-425.e6.	1.5	24
346	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Scientific Reports, 2018, 8, 208.	1.6	24
347	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2000, 8, 210-215.	2.0	23
348	Inclusion of CD80 in HSV Targets the Recombinant Virus to PD-L1 on DCs and Allows Productive Infection and Robust Immune Responses. PLoS ONE, 2014, 9, e87617.	1.1	23
349	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 19.	2.3	23
350	Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. Mucosal Immunology, 2021, 14, 1055-1066.	2.7	23
351	Protect the killer: CTLs need defenses against the tumor. Nature Medicine, 2002, 8, 787-789.	15.2	22
352	Cell-Intrinsic Abrogation of TGF-Î² Signaling Delays but Does Not Prevent Dysfunction of Self/Tumor-Specific CD8 T Cells in a Murine Model of Autochthonous Prostate Cancer. Journal of Immunology, 2012, 189, 3936-3946.	0.4	22
353	A new therapeutic strategy for malaria: targeting T cell exhaustion. Nature Immunology, 2012, 13, 113-115.	7.0	22
354	DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8+ T cells independently of PD-1 and PD-L1. International Immunology, 2013, 25, 651-660.	1.8	21
355	Down-Regulation of CTLA-4 by HIV-1 Nef Protein. PLoS ONE, 2013, 8, e54295.	1.1	20
356	PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8 ⁺ T cells in lymphoid tissue. Science Immunology, 2021, 6, eabh3034.	5.6	20
357	Role of the Immune Modulator Programmed Cell Death-1 during Development and Apoptosis of Mouse Retinal Ganglion Cells. , 2009, 50, 4941.		19
358	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica, 2021, 106, 1330-1342.	1.7	19
359	Upregulation of Interleukin 7 Receptor Alpha and Programmed Death 1 Marks an Epitope-Specific CD8⁺T-Cell Response That Disappears following Primary Epstein-Barr Virus Infection. Journal of Virology, 2009, 83, 9068-9078.	1.5	18
360	Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. Journal of General Virology, 2015, 96, 1463-1477.	1.3	17

#	Article	IF	Citations
361	Acidity changes immunology: a new VISTA pathway. Nature Immunology, 2020, 21, 13-16.	7.0	17
362	Mapping Temperature-sensitive Mutants of Vesicular Stomatitis Virus by RNA Heteroduplex Formation. Journal of General Virology, 1981, 57, 103-117.	1.3	16
363	BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. Oncotarget, 2015, 6, 19445-19455.	0.8	16
364	Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in nonâ€“small cell lung cancer. Science Advances, 2022, 8, eabi9533.	4.7	16
365	The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Mammalian Genome, 1997, 8, 581-582.	1.0	15
366	Characterization of Endogenous Chinese Hamster Ovary Cell Surface Molecules That Mediate T Cell Costimulation. Cellular Immunology, 2001, 213, 83-93.	1.4	15
367	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology, 2020, 21, 263.	3.8	15
368	Anti-CAIX BBÎ¶ CAR4/8 TÂcells exhibit superior efficacy in a ccRCC mouse model. Molecular Therapy - Oncolytics, 2022, 24, 385-399.	2.0	15
369	Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-Î² signaling in activated T lymphocytes. Blood, 2007, 109, 2944-2952.	0.6	14
370	Identification, by protein sequencing and gene transfection, of sgp-60 as the murine homologue of CD48.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3418-3422.	3.3	13
371	CD101 is expressed by skin dendritic cells Role in Tâ€lymphocyte activation Role in Tâ€lymphocyte activation. Tissue Antigens, 1997, 50, 439-448.	1.0	13
372	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. Journal of Clinical Oncology, 2014, 32, 467-467.	0.8	13
373	Blockade of RGMb inhibits allergen-induced airways disease. Journal of Allergy and Clinical Immunology, 2019, 144, 94-108.e11.	1.5	12
374	Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunology Research, 2022, 10, 680-697.	1.6	12
375	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	3.2	12
376	Expression of lectin-like transcript-1 in human tissues. F1000Research, 2016, 5, 2929.	0.8	11
377	New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016. , 2017, 5, 50.		10
378	Programmed death ligand 2 â€“ A link between inflammation and bone loss in rheumatoid arthritis. Journal of Translational Autoimmunity, 2020, 3, 100028.	2.0	10

#	Article	IF	Citations
379	Distinct Roles Of PD-1 Itsm and ITIM In Regulating Interactions With SHP-2, ZAP-70 and Lck, and PD-1-Mediated Inhibitory Function. Blood, 2013, 122, 191-191.	0.6	10
380	The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings. Frontiers in Immunology, 2022, 13, 773946.	2.2	9
381	Replenish the source within. OncoImmunology, 2013, 2, e25912.	2.1	8
382	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research, 2021, 9, 1465-1475.	1.6	8
383	Activation of human T cell lymphotropic virus type I-infected T cells is independent of B7 costimulation. Journal of Immunology, 1996, 157, 2932-8.	0.4	8
384	Effect of 5-fluorouracil on membranous PD-L1 expression in colon cancer cells.. Journal of Clinical Oncology, 2016, 34, 592-592.	0.8	7
385	Costimulatory Genes: Hotspots of Conflict between Host Defense and Autoimmunity. Immunity, 2013, 38, 1083-1085.	6.6	6
386	Ex Vivo Generation of Human Antiâ€“Pre-B Leukemia-Specific Autologous Cytolytic T Cells. Blood, 1997, 90, 549-561.	0.6	6
387	The murine Cd48 gene: allelic polymorphism in the IgVâ€like region. International Journal of Immunogenetics, 1998, 25, 421-423.	1.2	5
388	Comment on â€œTim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infectionâ€• Journal of Immunology, 2014, 193, 467-467.	0.4	5
389	Repulsive Guidance Molecule b (RGMb) Is Dispensable for Normal Gonadal Function in Mice1. Biology of Reproduction, 2016, 94, 78.	1.2	5
390	PD-L1 expression in non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 424-424.	0.8	5
391	The great debate at â€œImmunotherapy Bridge 2018â€• Naples, November 29th, 2018. , 2019, 7, 221.		4
392	Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. Blood Advances, 2019, 3, 3419-3431.	2.5	4
393	Abstract 572: Inhibition of IDO1 with epacadostat enhances anti-tumor efficacy of PD-1 blockade in a syngeneic glioblastoma (GBM) model. , 2017, , .		4
394	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2019, 37, 4568-4568.	0.8	4
395	In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation. Blood, 1997, 90, 4297-4306.	0.6	4
396	No evidence for MUC 1-induced apoptosis. Nature Medicine, 1998, 4, 1093-1093.	15.2	3

#	Article	IF	Citations
397	PD-1 Inhibits TCR Proximal Signaling By Sequestering SHP-2 Phosphatase and Facilitating Csk-Mediated Inhibitory Phosphorylation of Lck. Blood, 2015, 126, 283-283.	0.6	3
398	Definition of T-cell specific DNA-binding factors that interact with a 3â€²-silencer in the CD4+ T-cell gene Rpt-1. Gene, 1989, 85, 461-469.	1.0	2
399	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. Blood, 2018, 132, 1579-1579.	0.6	2
400	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. Blood, 2018, 132, 1446-1446.	0.6	2
401	Rap1-GTP Promotes the Generation of Regulatory T Cells in Vivo.. Blood, 2004, 104, 110-110.	0.6	2
402	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. Blood, 2014, 124, 74-74.	0.6	2
403	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. Journal of Clinical Oncology, 2018, 36, 619-619.	0.8	2
404	The E3 Ubiquitin Ligase TRIM36, a Transcriptional Target of Tob, Is Expressed in Anergic T Cells and Mediates Unresponsiveness through Proteolysis of Signaling Proteins PLC- Î³1 and PKC-?.. Blood, 2004, 104, 113-113.	0.6	2
405	JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression. Blood, 2013, 122, 3472-3472.	0.6	2
406	B7 (CD80 and CD86). , 1998, , 304-308.		1
407	Anti-Programmed Death 1 (PD1). , 2017, , 57-66.		1
408	PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. Annals of Oncology, 2018, 29, viii726.	0.6	1
409	Abstract 4359: Rescue of exhausted CD8 T cells by PD-1 targeted therapies is CD28-dependent. , 2016, , .		1
410	Abstract 4713: BET bromodomain inhibition synergizes with PD-1 blockade to facilitate anti-tumor response inKras-mutant non-small cell lung cancer. , 2018, , .		1
411	Abstract 3779: Clonal tracing reveals different mechanisms of resistance to immune checkpoint blockade. , 2019, , .		1
412	Interaction of Both SH2 Domains of SHP-2 with a PD-1 Homodimer Is Required for PD-1-Mediated Inhibition of T Cell Responses. Blood, 2016, 128, 859-859.	0.6	1
413	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. Journal of Clinical Oncology, 2016, 34, e23221-e23221.	0.8	1
414	PD-L1 expression in Epstein-Barr virus-infected gastric cancers.. Journal of Clinical Oncology, 2016, 34, 4052-4052.	0.8	1

#	Article	IF	Citations
415	Su.54. Programmed Cell Death-1 Regulates Neuronal Cell Death in the Developing Mouse Retina. Clinical Immunology, 2008, 127, S141-S142.	1.4	0
416	T.2.5. PD-L1 Regulates the Development, Maintenance and Function of Induced-regulatory T Cells. Clinical Immunology, 2009, 131, S45.	1.4	0
417	T.14.5. TIM-4 Negatively Regulates Immune Responses by Reducing Antigen Specific T Cell Numbers. Clinical Immunology, 2009, 131, S53.	1.4	0
418	Novel Role of PD-L1 in Regulating T Cell Homing to the Small Intestine. Gastroenterology, 2011, 140, S-488.	0.6	0
419	IT-29 * IMMUNE CHECKPOINT BLOCKADE FOR GLIOBLASTOMA: PRECLINICAL ACTIVITY OF SINGLE AGENT AND COMBINATORIAL THERAPY. Neuro-Oncology, 2014, 16, v116-v116.	0.6	0
420	TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd. Biology of Blood and Marrow Transplantation, 2016, 22, S398-S399.	2.0	0
421	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS AÂBIOMARKER FOR IMMUNOTHERAPY. Neuro-Oncology, 2017, 19, vi114-vi114.	0.6	0
422	Bone Morphogenetic Protein Signaling Pathway Modulation by Blocking Anti-Repulsive Guidance Molecule B Antibody Promotes Tolerance in Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, S324.	2.0	0
423	IMMU-19. PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION. Neuro-Oncology, 2018, 20, vi125-vi125.	0.6	0
424	PDâ€1 negatively regulates CD8 T cellâ€mediated mucosal autoimmunity. FASEB Journal, 2008, 22, 852.4.	0.2	0
425	PDâ€L1 interaction limits excessive Th1 effector function during Mycobacterium tuberculosis infection. FASEB Journal, 2008, 22, 663.20.	0.2	0
426	Marrow-Infiltrating T Cells In Patients with Chronic Lymphocytic Leukemia Display Markers of Functional Impairment and Express PD-1. Blood, 2010, 116, 2417-2417.	0.6	0
427	Ex Vivo Expansion of Donor-Derived Anti-Tumor T Cells for CLL-Specific Adoptive Immunotherapy. Blood, 2011, 118, 978-978.	0.6	0
428	Anti-Programmed Death 1 (PD1). , 2013, , 1-10.		0
429	Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model. Blood, 2013, 122, 292-292.	0.6	0
430	Induction of Alloantigen Specific T Cell Anergy by Inhibition of the B7: CD28 Pathway. , 1995, , 205-218.		0
431	B7-Deficient Mice Reveal an Alternative Functional CTLA-4 Counterreceptor. , 1996, , 107-120.		0
432	The Regulatory Functions of Co-Stimulators Revealed in Transgenic Mice. , 1996, , 101-106.		0

#	Article	IF	Citations
433	Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease. Blood, 2015, 126, SCI-8-SCI-8.	0.6	0
434	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. Journal of Clinical Oncology, 2016, 34, 4535-4535.	0.8	0
435	Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL). , 2016, , .		0
436	Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition. , 2016, , .		0
437	Abstract 4027: Recurrent gains of CD274 (PD-L1) and PDCD1LG2 (PD-L2) provide a genetic basis for PD-1 ligand expression in a subset of solid tumors. , 2016, , .		0
438	Abstract A075: Preclinical analysis of combinatorial glioblastoma therapy with the prodrug-mediated gene therapy vector AdV-TK and immune checkpoint inhibition in GBM therapy. , 2016, , .		0
439	Abstract A097: Tumor PDL1 blocks CTL cytotoxicity. , 2016, , .		0
440	Abstract B84: Preclinical analysis of combinatorial glioblastoma therapy with the prodrug-mediated gene therapy vector AdV-TK and immune checkpoint inhibition. , 2017, , .		0
441	Abstract A56: Identification and characterization of an alternative cancer-derived PDL1 isoform. , 2017, , .		0
442	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	0.8	0
443	Abstract 417: Defining molecular mechanisms of resistance to glioblastoma immunity using a novel CRISPR/Cas9in vivoloss-of-function screening platform. , 2017, , .		0
444	Abstract 1686: TSC2 enhances antitumor immunity and potentiates PD-1 and CTLA-4 blockade. , 2018, , .		0
445	Abstract 4048: Comprehensive analysis of the suppressed tumor immune microenvironment of CIN gastro-esophageal adenocarcinomas. , 2018, , .		0
446	Abstract A12: Identification of resistance to immune checkpoint blockade. , 2018, , .		0
447	Abstract A15: Immune-related changes in breast cancer tumor evolution. , 2018, , .		0
448	Abstract A19: PD-1 modulation promotes antitumor immunity by improving metabolic fitness of both PD-1+ and PD-1- CD8+ T cells in the tumor. , 2018, , .		0
449	The Two SH2 Domains of SHP-2 Bridge Two PD-1 Molecules Resulting in SHP-2 Activation and PD-1-Mediated Inhibition. Blood, 2018, 132, 862-862.	0.6	0